WHO ICTRP trial
Efficacy and safety of Polyethylene Glycol Loxenatide in combination with…
ChiCTR2100045608 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2100045608 |
|---|---|
| Public title | Efficacy and safety of Polyethylene Glycol Loxenatide in combination with Canagliflozin in patients with type 2 diabetes mellitus at high risk for secondary prevention of heart and kidney disease |
| Scientific title | Efficacy and safety of Polyethylene Glycol Loxenatide in combination with Canagliflozin in patients with type 2 diabetes mellitus at high risk for secondary prevention of heart and kidney disease: a prospective, multicenter, randomized controlled, open-label study |
| Primary sponsor | West China Hospital Sichuan University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 4 |
| Countries | China |
| Conditions | Type 2 Diabetes |
| Interventions | experimental group:Polyethylene Glycol Loxenatide + Canagliflozin;control group:Metformin+ Canagliflozin |
| Registration date | Apr 19, 2021 |
| Target size | experimental group:500;control group:500 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: